Pseudobulbar affect (PBA), also known as pathological

Size: px
Start display at page:

Download "Pseudobulbar affect (PBA), also known as pathological"

Transcription

1 Introduction to Pseudobulbar Affect: Setting the Stage for Recognition and Familiarity With This Challenging Disorder Tammie Lee Demler, PharmD, MBA, BCPP Pseudobulbar affect (PBA), also known as pathological laughter and crying, affects approximately 2 million Americans. 1 The causes of PBA are complex, but it is believed to result from the alteration of neuronal pathways, primarily in the frontal lobe of the brain, which control emotions. 2 Symptoms suggestive of PBA commonly occur in individuals diagnosed with Parkinson disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer disease (AD), traumatic brain injury (TBI), and stroke. 1 Pseudobulbar affect (PBA) was first recognized in the 19th century 3 ; however, despite being extensively described before 1940, PBA is perceived as a relatively new disease today. 1 In 1886, Oppenheim and Siemerling discussed individuals with lesions along the brainstem s descending pathways with inflated emotional behavior. 4,5 The behavior was described as spasmodic explosive outbursts of laugher or weeping and was termed pseudobulbar affect. 1,6 One of the oldest descriptions of pathological laughing and crying is described by French surgeon, Ambroise Paré, during the 16th century. 7 PBA has been labeled emotional lability, emotional incontinence, involuntary emotional expression disorder, emotional dysregulation, emotionalism, or pathological laughing and crying. 4,8-10 The patient s laughter or crying does not always coincide with the mood or intensity of the experience the patient describes, the current social situation, or stimuli; PBA may also be elicited without a stimulus. 4,8 Patients with PBA may have an appropriate response that is more intense, recurring, and hyperbolic. 4 These responses may also be uncharacteristic of the patient, such as excessive crying in a patient who rarely cried prior to the onset of PBA. 4 PBA is often misdiagnosed as a psychiatric disorder, such as depression, or underrecognized in patients with conditions whose symptoms mimic those of PBA. 3 Unlike patients diagnosed with mood disorders, those with PBA have unsustained, explosive, and irregular emotional responses. 4,11 PBA occurs most commonly among patients who have PD, multiple sclerosis, amyotrophic lateral sclerosis or AD or have experienced a traumatic brain injury, stroke and other neurological diseases that damage the central nervous system. 1 Patients and caregivers report experiencing embarrassment and a decreased quality of life, which ABSTRACT Pseudobulbar affect (PBA), despite its prevalence and distinctive symptoms, is widely underrecognized and undertreated. It is characterized by uncontrollable laughing or crying that can occur in an exaggerated manner or inappropriately to a given situation or stimuli. PBA is thought to center around preexisting neurological conditions, which include Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer disease, traumatic brain injury, and stroke. The PBA Registry Series trial was created to measure the prevalence of PBA among patients with these underlying neurological conditions. Through greater awareness, recognition, and diagnosis, treatment for patients with PBA can be improved. Am J Manag Care. 2017;23:S339-S344 For author information and disclosures, see end of text. THE AMERICAN JOURNAL OF MANAGED CARE Supplement VOL. 23, NO. 18 S339

2 may lead to disruptions in their social lives, including isolation and loss of employment. 6 It is a significant national health issue in the United States, occurring in greater numbers of individuals than those affected by PD, MS, or ALS alone Parkinson Disease In the United States, an estimated 1 million individuals, which is more than the combined number of patients who have been diagnosed MS or ALS, have a PD diagnosis. 12 Worldwide, that number is 10 million. 12 Every year in the United States, roughly 60,000 individuals are diagnosed with PD, not including the thousands who remain undiagnosed. 12 PD is a chronic and progressive movement disorder with symptoms that persist and worsen over time. The symptoms and degree to which one experiences these are highly individualized, but symptoms typically include tremors of the hands, arms, legs, jaw, and face; bradykinesia, or slowness of movement; rigidity or stiffness of the limbs and trunk; and postural instability or impaired balance and coordination. There is currently no cure, although most patients are managed with medication and/or surgery. Like PBA, the cause of PD is unknown, although research has facilitated a better understanding of this disease. 15 PD involves the malfunction and death of vital neuronal cells in the brain, primarily the substantia nigra where neurons produce dopamine, the neurotransmitter that controls movement and coordination. As PD progresses, the amount of dopamine produced in the brain decreases, leaving a person unable to control movement. The combined direct and indirect costs of PD, including treatment, Social Security payments, and lost income from an inability to work, are estimated to be nearly $25 billion per year in the United States alone. 12 According to the PBA Registry Series (PRISM) trial, which will be described in greater detail later in this supplement, roughly 26% of patients with a PD diagnosis have symptoms suggestive of PBA. 1 Multiple Sclerosis MS is a chronic inflammatory and neurodegenerative disease that is a consequence of an abnormal response of the body s immune system, which directs an immune-mediated process against the central nervous system. Targets include, but are not limited to, the nerve fibers in the brain, spinal cord, and optic nerves. This immune attack is also waged against the fatty myelin substance that covers the nerve fibers, resulting in scarring (or sclerosis). Although the cause is unknown, activation of the disease is hypothesized to be triggered by environmental causes in genetically susceptible individuals. MS affects approximately 400,000 people in the United States and adversely affects quality of life (QOL), employment, social relationships, and patients productivity. 13,16 The total all-cause healthcare costs associated with MS, including direct and indirect costs, in the United States ranges from $8528 to $52,244 per patient per year, which equates to $20.8 billion for all patients annually. 17 According to the PRISM trial results, approximately 46% of patients diagnosed with MS have symptoms suggestive of PBA. 1 Amyotrophic Lateral Sclerosis ALS, also known as Lou Gehrig disease, is a progressive neurological disease that mainly involves neurons responsible for controlling voluntary muscle movements such as swallowing, breathing, talking, and walking. When symptoms begin in the arms or legs, it is referred to as limb-onset ALS. Other individuals first notice speech or swallowing problems, which is termed bulbar-onset ALS. The deterioration, degeneration, and death of motor neurons extending from the brain to the spinal cord and to muscles throughout the body cause the symptoms of ALS. These usually include muscle weakness or stiffness, with later progression to loss of strength in all muscles under voluntary control. The CDC has estimated that between 14,000 and 16,000 Americans have ALS, which is a much smaller economic impact than PD or MS in comparative numbers. 14 Regardless of the prevalence, ALS is severely debilitating for those diagnosed with the disease. Although the cause is unknown, several potential risk factors for ALS include being male, white, and between the ages of 60 and 69 years. 14 Because military veterans are twice as likely to develop ALS, the hypothesis that environmental toxins may trigger the disease has facilitated the recognition of ALS as a service-connected disease by the US Department of Veterans Affairs. 18 According to the PRISM trial results, roughly 45% of patients diagnosed with ALS also have symptoms suggestive of PBA. 1 Alzheimer Disease AD is the most common form of dementia, which is a general term for memory loss and other cognitive capacity that impacts daily life. AD accounts for up to 80% of dementia cases. 19 AD is not considered a normal part of aging and is a progressive disease that worsens over time. Although current medication therapy does not cure or prevent AD from progressing, these agents can temporarily slow the worsening of dementia symptoms and improve QOL for those with AD and their caregivers. There are roughly 5.5 million Americans living with AD dementia in 2017, with most of these patients 65 years or older, and this number is growing quickly. 19 Although the cause is unknown, several potential risk factors for AD include being 65 years or older, female, and black and/or Hispanic. 19 Elderly patients with dementia have twice as many annual hospitalizations as elderly patients without dementia. 19 Additionally, patients with dementia who have Medicare are more likely than patients without dementia to have other chronic disorders. 19 The total annual payments (health, long-term, and hospice care) for people with AD or other dementias are slated to rise from $259 billion in 2017 to in excess of $1.1 trillion by This astounding increase contains more than a 4-fold growth in Medicaid and Medicare government spending and out-of-pocket spending. 19 S340 NOVEMBER

3 INTRODUCTION TO PSEUDOBULBAR AFFECT According to the PRISM trial results, roughly 30% of patients diagnosed with AD also have symptoms suggestive of PBA. 1 Traumatic Brain Injury and Stroke The diagnosis of PBA in patients with brain injury resulting from a TBI and stroke is challenging and often misdiagnosed. 20 Brain injuries resulting from TBI and stroke were also considered in the PBA patient spectrum in PRISM. According to the PRISM trial results, roughly 53% and 38% of patients diagnosed with these conditions, respectively, have symptoms suggestive of PBA. 1 TBI is described as, an alteration in brain function, or other evidence of brain pathology, caused by an external force. 21 TBI caused by combat, sports, and minor accidents may have harmful results and lead to a reduction in brain reserve and protection against various brain disorders with late onset. 22 In a single game, National Football League (NFL) players may be hit 30 to 50 times in the head. 22 This may result in subdural hematomas, decreased cognition, and death. 22 A highly publicized result of TBI in professional football players is chronic traumatic encephalopathy (CTE), a condition believed to be caused by tau tangles in the brain. 23 Symptoms of CTE include changes in mood and behavior, headaches, Parkinsonism, and a decrease in coordination. 23 Currently, there is debate around the link between CTE and dementia, particularly in those with concussions, and a lack of clinical criteria to diagnose CTE. 23,24 As a reason to question these postulations, skeptics cite samples of convenience used as case reports to derive the clinical and pathological CTE data, samples from athletes whose autopsies were requested because the person experienced neuropsychiatric symptoms as opposed to a randomly sampled group. 23,25,26 However, results of a study by Mez et al of 202 American football players showed a diagnosis of CTE in 87% of players from all levels of football and 99% in NFL players. 27 The authors noted further investigation is warranted, as CTE is not a rare disease, and the sample was one of convenience derived from donors. Incidence and Prevalence It is estimated that up to 2 million Americans have PBA with some sources suggesting that up to 7 million individuals in the United States exhibit symptoms suggestive of PBA. 1,8,28 Despite this large population, there is new recognition that PBA is both underdiagnosed and undertreated. 1 The varying individualized symptoms associated with PBA complicate efforts to further determine prevalence. 1,4,29 PRISM was created to collect prevalence data from patients with symptoms due to common neurological disorders in a large, representative sample of the US population. 1 The registry was designed to collect information from 10,000 patients at 500 sites nationwide with the following 6 conditions: PD, MS, ALS, AD, TBI, or stroke. 1 A total of 5290 patients enrolled in the PRISM registry. 1 The characteristics of PRISM patients are listed in Table 1 1. The TABLE 1. PRISM Patient Characteristics 1 Total number of patients (N) 5290 Average age (years) 65.8 Age 65 or older 57.6% Age 75 or older 39.6% Female 60.2% Neurological conditions Parkinson s disease 804 (15.2%) Multiple sclerosis 1215 (23.0%) Alzheimer s disease 1799 (34.0%) Amyotrophic lateral sclerosis 125 (2.4%) Stroke 757 (14.3%) Traumatic brain injury 590 (11.2%) lowest average age was in the TBI and MS groups, roughly 48 years. 1 A mean of 6.7 years was recorded as the time since the diagnosis of the underlying primary neurological condition, but this item was only recorded for 50.6% of the sample. 1 The presence of PBA symptoms was defined as a Center for Neurologic Study-Lability Scale (CNS-LS) score A CNS-LS score 21 was also evaluated to determine the prevalence of PBA in patients with more severe and recurrent symptoms. 1,29,30 The CNS-LS was the first validated tool used to measure symptoms of PBA by self-report. 1,31 It is divided into subscales used to measure crying (3 items) and laughter (4 items). 1,31 Each item is scored from 1 (applies never) to 5 (applies most of the time), and the cumulative scoring may range from 7 to 35. 1,31 The CNS-LS and an 11-point QOL scale assessing the impact of neurological disorders was completed by either the patient or the patient s caregiver. 1 A total of 36.7% of patients had CNS-LS scores 13 and 9.3% had CNS-LS scores Patients with PD (26.0%) had the smallest group with CNS-LS scores 13 and TBI patients the highest, at 52.4%. Higher CNS-LS scores were associated with lower QOL scores. The prevalence of neurological diagnoses in patients 65 years in the PRISM trial was greatest in most categories, with the exception of ALS, MS, and TBI. The percentage breakdown is as follows: AD = 1660 (54.5%), PD = 639 (21.0%), MS = 112 (3.7%), ALS = 54 (1.8%), stroke = 476 (15.6%), and TBI = 107 (3.5%). 1 Although more females were enrolled in the registry, males were represented in a higher percentage in the ALS and PD populations. 1 The differences in prevalence by age are unclear, but do not appear to be explained by a difference in the relative percentage of underlying neurological conditions between younger and older patients. 1 Etiology There has been more focus on PBA recently, especially since the FDA approval for a medication specific for this condition. 32 Despite earlier THE AMERICAN JOURNAL OF MANAGED CARE Supplement VOL. 23, NO. 18 S341

4 TABLE 2. Reported Criteria Associated With PBA Manifestations 9,20 Episodes are not congruent to the situation and may be triggered by nonspecific stimuli. Episodes not in line with or extremely exaggerated compared with the patient s current mood and occur in an inappropriate situation or with an involuntary attribute at onset. Episodes are different from the patient s usual emotional response, may be inconsistent with or in excess of the patient s current mood, and are independent or in excess of inciting stimuli. Spontaneous or exaggerated expressions of emotion. PBA indicates pseudobulbar affect. Poeck formulated the following criteria in The patient s emotional expression and current mood do not closely correlate and patient does not experience any relief while expressing the affects and episodic changes in mood correlating to the episodes. Cummings and Rosen emphasized major PBA criteria 9 uses of dextromethorphan with quinidine, little was understood about this emotional lability, the associated reflexive episodes of laughter and tearfulness, and the proposed mechanism by which these compounds were effective in controlling these symptoms. 8 The pathways related to PBA are multifaceted and thought to result from disruptions of neural networks that control the generation and regulation of motor output of emotions. 8 PBA is associated with brain injury or a neurological disease or disorder that alters normal neuronal control and affect likely linked to frontal lobe function and other areas of the brain, such as the brainstem and cerebellum. 2 Brain lesions located mostly in the frontal lobes and descending pathways to the brainstem, basis pontis, and cerebellum, which encompass systems thought to be involved in motor control of emotional expression, are linked to PBA. 2 One of the original hypotheses regarding the pathophysiology of PBA proposed that there was a disruption of the cortical inhibition to an upper brainstem center followed by release of lower bulbar nuclei that coordinate the motor response connected with laughing and crying. 33 An additional hypothesis is that a dysfunction in the connection between the cerebellum and cerebral cortex leads to a disruption in emotional regulation. 4,34 Risk Factors The underlying mechanisms associated with developing PBA are not fully understood. PBA is associated with brain injury and neurological disorders, many of which are associated with demographic predictors but otherwise have unknown origin; however, TBI and stroke are often preventable. The leading known causes of TBI in adults 65 years and older are falls and motor vehicle crashes. 35 When addressing fall prevention in the elderly, identifying risk factors and patient education is key. Risk factors include issues with shoes and/or feet, poor vision, postural dizziness, gait and balance problems, psychoactive medications, lower body weakness, and home safety. Healthcare providers should educate patients about these risks and modify medications, if applicable; prevent hypotension; optimize vision; monitor for foot problems, and promote the importance of home safety. 36,37 Wearing motorcycle helmets and seat belts and avoiding alcohol-impaired driving can decrease the risk of motor vehicle-associated TBI. 35 Cardiovascular risk factors affect cognition as we age and are major contributors to the risk for conditions such as AD and stroke. 38 According to the American Heart Association (AHA) and American Stroke Association, individuals can take actions to promote optimal brain health. These actions, termed the AHA s Life s Simple 7, include ideal health factors and behaviors that include, but are not limited to, controlling weight, blood pressure, blood glucose, and total cholesterol, and smoking cessation. Physical activity 4 or more times per week for more than 75 minutes with vigorous intensity and 150 minutes with moderate intensity and a healthy diet consisting of mainly fruits and vegetables, fish, and fiber-rich whole grains, with limited consumption of sodium and sugar-sweetened items, account for the suggested ideal health behaviors. 38,39 Difficulty in controlling episodes and episodes that build up and resolve in a stepwise manner. The necessity of a wait-out period for the patient to return to his or her prior activity. This usually takes anywhere from a few seconds to minutes. Cummings et al 20 Disturbances caused by repetitive episodes result in social or occupational functional impairment or significant clinical distress. The symptoms are not elicited by a direct effect of a substance. No other psychological or neurological disorders account for the patient s symptoms. Clinical Presentation PBA episodes are generally perceived to be unprovoked and out of proportion to the mood the patient is experiencing. The degree of emotional response is often considered extreme and unable to be voluntarily suppressed by the patient. Tearfulness is reported to be a more common PBA manifestation than laughter. 8 PBA (especially crying-predominant PBA) has been reported to be more prevalent in women with ALS. 40 Criteria common to PBA seen in TBI were reported by Poeck and Cummings et al, but others have also cited associated findings (Table 2 9,20 ). 19,20 S342 NOVEMBER

5 INTRODUCTION TO PSEUDOBULBAR AFFECT Symptoms Untreated PBA can be very distressing and embarrassing and can cause anxiety and social dysfunction, thus negatively affecting day-to-day functions, relationships, overall QOL, and patient productivity, as well as increasing the caregiver burden. The symptoms can be severe, with persistent, incessant episodes having an abrupt unpredictable onset. Some patients describe the feeling associated with the onset of a PBA episode as comparable to the start of a seizure; the duration of an outburst can be a few seconds to several minutes and may occur several times a day. Symptoms suggestive of PBA in nursing homes present in 17.5% of residents with neurological conditions and 9% of residents overall. 41 Symptoms suggestive of PBA were observed in an estimated 45% and 70% of patients diagnosed with dementia or HIV-dementia, respectively. 42 More research to validate the findings (especially in patients with HIV-dementia) and more refined screening tools should be developed for patients who exhibit PBA symptoms. Frequently co-occurring psychiatric disorders, especially depression (35%), can present with symptoms similar to PBA. 8 PBA and depression must be considered separate conditions and treated accordingly. Symptoms such as fatigue, anorexia, insomnia, and feelings of hopelessness and guilt are not linked with PBA. Depressive symptoms classically last weeks to months, but a PBA episode only lasts seconds or minutes. Also, crying, as a symptom of PBA, might be unrelated or inflated relative to the patient s mood, but crying is consistent with subjective mood in depression. Impact The cost of PBA includes not only financial aspects, but also those associated with the patient s QOL. In a study by Palmgren et al that examined data from a large US national healthcare insurer, the annual weighted costs of hospitalizations were $12,394 per patient. 43 Additionally, the annual weighted costs of emergency department visits were $1664 per patient. 43 Although we understand there is a financial impact, there are also QOL impacts on the patients. 43 When interpreting the QOL scale used in PRISM,the higher the score, the greater the negative impact (more adverse). 1 Patients with PBA symptoms reported significantly worse mean QOL scores due to neurological conditions. QOL scores were the worst for all categories (PD, MS, ALS, AD, TBI, and stroke) and statistically significant for all but ALS (likely due to the small sample size). The QOL scale rated the impact on a scale of 1 (not at all) to 10 (strongly affected), all patient self-reported in response to How has your neurological condition affected your quality of life? (Table 3 1 ). Similar to the QOL reported in the overall patient sample, patients 65 years with PBA symptoms had significantly higher mean scores for the impact of a neurological condition on QOL (6.3 for CNS-LS 13 vs 4.6 for CNS-LS <13; P <.0001, 2-sample t-test). 1 The TABLE 3. Quality-of-Life Scores of Patients With PBA Symptoms Categorized by Underlying Neurological Condition 1 PBA Symptom Prevalence by Neurological Disease (total patients = 5290) QOL impact parallels the findings from other studies, including the MOS 36-item short-form health survey (SF-36). 44 Burden of Impact Quality-of-life Rating for Patients With CNS-LS 13 (suggestive of PBA) Quality-of-life Rating for Patients With CNS-LS <13 (not suggestive of PBA) TBI 52.4% (n = 590) MS 45.8% (n = 1215) ALS 44.8% (n = 125) Stroke 37.8% (n = 757) AD 29.3% (n = 1799) PD 26% (n = 804) AD indicates Alzheimer disease; ALS, amyotrophic lateral sclerosis; CNS-LS, Center for Neurologic Study-Lability Scale; MS, multiple sclerosis; PBA, pseudobulbar affect; PD, Parkinson s disease; TBI, traumatic brain injury. Patients with PBA are aware of social norms and the inappropriateness of their responses. Thus, they are embarrassed by the inability to control these involuntary outbursts. 4 This may lead to subsequent restriction of social interactions and a lower QOL. 8 Subsequently, relationships may suffer, resulting in loss of those relationships, including divorce, and patients may become homebound. 30 A study assessing the burden of illness across multiple measures and areas of function in patients suffering from PBA, such as social, occupational, and relationship problems, reported an example of how PBA affects patients. 3,30 Results showed that patients and caregivers with PBA were less likely to be employed, likely due to a decrease in productivity at and outside of work and absenteeism from work. 30 Patients with PBA are challenged by the underlying disorder as well as the accompanying emotional changes, thus often resulting in even more anxiety, depression, and other comorbid psychiatric illness and impairment compared with their non-pba peers in the community. 30 Another study evaluated the adverse impact of PBA symptoms and suggested that the symptoms alone, regardless as to whether they also had a posttraumatic stress disorder diagnosis, led to greatly decreased QOL and considerably increased healthcare costs. 45 Caregivers experience a substantial burden when caring for patients with PBA. Compared with caregivers of patients with the same underlying neurological conditions without PBA, they experience a significantly increased illness burden. 30 They feel uncertainty and embarrassment and lack the tools to handle these unpredictable outbursts. This can lead to even greater reduction in an already impaired degree, because of the underlying neurological disorder, of socialization, isolation, and lower QOL indices. 30 We know that from other neurological conditions, such as dementia, THE AMERICAN JOURNAL OF MANAGED CARE Supplement VOL. 23, NO. 18 S343

6 that behaviors that cannot be controlled by caregivers are often the catalyst for earlier unnecessary institutionalization. 46 Elderly participants with varying degrees of cognitive impairment were more likely to have a shorter time to nursing home placement if they exhibited symptoms of behavioral, psychological, or poor physical health. 47 Support for both the patients with PBA and their caregivers is essential in decreasing their burden of care and decline in health. Conclusion PBA is often unrecognized and misdiagnosed. Patients with PBA experience episodes of spontaneous or exaggerated laughter and/ or crying that are disproportionate to or inappropriate for the current situation. It is often mistaken for mental health conditions such as depression and hidden by the symptoms of the commonly associated diseases ALS, TBI, MS, stroke, and AD. Both patients and caregivers often feel embarrassed, experience reduced QOL, and require support to help manage PBA. Raising awareness of PBA through the education of healthcare professionals, patients, families, caregivers, and the public may result in increased recognition and better management of PBA. n Author affiliation: SUNY Buffalo School of Pharmacy and Pharmaceutical Sciences and SUNY Buffalo School of Medicine, Buffalo, NY. Funding source: This activity is supported by an independent educational grant from Avanir Pharmaceuticals, Inc. Author disclosures: Dr Demler has no relevant financial relationships with commercial interests to disclose. Authorship information: Analysis and interpretation of data; concept and design; critical revision of the manuscript for important intellectual content; drafting of the manuscript; supervision. Address correspondence to: TammieLee.Demler@omh.ny.gov. REFERENCES 1. Brooks BR, Crumpacker D, Fellus J, Kantor D, Kaye RE. PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions. PLoS One. 2013;8(8):e doi: /journal.pone Brooks BR, Thisted RA, Appel SH, et al; AVP-923 ALS Study Group. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63(8): Sauvé WM. Recognizing and treating pseudobulbar affect. CNS Spectr. 2016;21(S1): doi: /S Parvizi J, Coburn KL, Shillcutt SD, Coffey CE, Lauterbach EC, Mendez MF. Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci. 2009;21(1): doi: /appi.neuropsych Oppenheim H, Siemerling E. Mitteilungen uber Pseudobulbarparalyse und akute Bulbarparalyse. Berl kli Woch. 1886; Oppenheim H. Textbook of Nervous Diseases for Physicians and Students by Professor H. Oppenheim of Berlin. London, UK: TN Foulis; Altschuler E, Wisdom S. An old case of pathological laughing and crying. Lancet. 1999;354(9191):1736. doi: /S (05) Ahmed A, Simmons Z. Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag. 2013;9(1): doi: /TCRM.S Cummings JL. Involuntary emotional expression disorder: definition, diagnosis, and measurement scales. CNS Spectr. 2007;12(4 suppl 5): Parvizi J, Arciniegas DB, Bernardini GL, et al. Diagnosis and management of pathological laughter and crying. Mayo Clin Proc. 2006;81(11): doi: / Poeck K. Pathophysiology of Emotional Disorders Associated with Brain Damage, in Disorders of Higher Nervous Activity. Amsterdam, the Netherlands: Elsevier; Statistics on Parkinson s. Parkinson s Disease Foundation website. parkinson.org/understanding- Parkinsons/Causes-and-Statistics/Statistics. Accessed October 24, Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(suppl 5):S139-S Mehta P, Kaye W, Bryan L, et al. Prevalence of amyotrophic lateral sclerosis United States, MMWR Surveill Summ. 2016;65(8):1-12. doi: /mmwr.ss6508a What causes Parkinson s? Parkinson s Disease Foundation website. parkinson.org/understandingparkinsons/what-is-parkinsons. Accessed October 30, Ringold S, Lynm C, Glass RM. JAMA patient page. Systemic lupus erythematosus. J Am Med Assoc. 2005;293(4):514. doi: /jama Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5): doi: / Military veterans: resources for military veterans, families & survivors. The ALS Association website. alsa.org/als-care/veterans/. Accessed October 4, Alzheimer s Association Alzheimer s disease facts and figures. Alzheimers Dement. 2017;13(4): doi: /j.jalz Engelman W, Hammond FM, Malec JF. Diagnosing pseudobulbar affect in traumatic brain injury. Neuropsychiatr Dis Treat. 2014;10: doi: /NDT.S Menon DK, Schwab K, Wright DW, Maas AI. Position statement: definition of traumatic brain injury. Arch Phys Med Rehabil. 2010;91(11): doi: /j.apmr Kiraly MA, Kiraly SJ. Traumatic brain injury and delayed sequelae: a review - traumatic brain injury and mild traumatic brain injury (concussion) are precursors to later-onset brain disorders, including early-onset dementia. Sci World J. 2007;7: doi: /tsw Rao R, Syeda A, Roy D, Peters ME, Vaishnavi S. Neuropsychiatric aspects of concussion: acute and chronic sequelae. Concussion. 2017;2(1). doi: /cnc Godbolt AK, Cancelliere C, Hincapié CA, et al. Systematic review of the risk of dementia and chronic cognitive impairment after mild traumatic brain injury: results of the international collaboration on mild traumatic brain injury prognosis. Arch Phys Med Rehabil. 2014;95(suppl 3). doi: /j.apmr Wortzel HS, Brenner LA, Arciniegas DB. Traumatic brain injury and chronic traumatic encephalopathy: a forensic neuropsychiatric perspective. Behav Sci Law. 2013;31(6): doi: /bsl Karantzoulis S, Randolph C. Modern chronic traumatic encephalopathy in retired athletes: What is the evidence? Neuropsychol Rev. 2013;23(4): doi: /s Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA. 2017;318(4): doi: /jama Miller A, Pratt H, Schiffer RB. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother. 2011;11(7): doi: /ern Work SS, Colamonico JA, Bradley WG, Kaye RE. Pseudobulbar affect: an under-recognized and undertreated neurological disorder. Adv Ther. 2011;28(7): doi : /s Colamonico J, Formella A, Bradley W. Pseudobulbar affect: burden of illness in the USA. Adv Ther. 2012;29(9): doi: /s Moore SR, Gresham LS, Bromberg MB, Kasarkis EJ, Smith RA. A self report measure of affective lability. J Neurol Neurosurg Psychiatry. 1997;63(1): doi: /jnnp Nuedexta. Centerwatch website. centerwatch.com/drug-information/fda-approved-drugs/drug/1125/ nuedexta-dextromethorphan-hydrobromide-and-quinidine-sulfate. Accessed September 21, King RR, Reiss JP. The epidemiology and pathophysiology of pseudobulbar affect and its association with neurodegeneration. Degener Neurol Neuromuscul Dis. 2013;3: doi: /DNND.S Parvizi J. Pathological laughter and crying: a link to the cerebellum. Brain. 2001;124(9): doi: /brain/ CDC. CDC grand rounds: reducing severe traumatic brain injury in the United States. MMWR Morb Mortal Wkly Rep. 2013;62(27): CDC. Stopping elderly accidents, deaths & injuries (STEADI) - older adult fall prevention. STEADI materials for health care providers. CDC website. cdc.gov/steadi/. Updated March 23, Accessed September 20, Stevens JA, Phelan EA. Development of STEADI: a fall prevention resource for health care providers. Health Promot Pract. 2013;14(5): doi: / Gorelick PB, Furie KL, Iadecola C, et al; American Heart Association/American Stroke Association. Defining optimal brain health in adults. Stroke. 2017;48(10):e284-e303. doi: /STR Lloyd-Jones DM, Hong Y, Labarthe D, et al; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association s strategic impact goal through 2020 and beyond. Circulation. 2010;121(4): doi: /CIRCULATIONAHA Thakore NJ, Pioro EP. Laughter, crying and sadness in ALS. J Neurol Neurosurg Psychiatry. 2017;88(10): doi: /jnnp Foley K, Konetzka RT, Bunin A, Yonan C. Prevalence of pseudobulbar affect symptoms and clinical correlates in nursing home residents. Int J Geriatr Psychiatry. 2016;31(7): doi: /gps Cruz M. Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing. Pharm Ther. 2013;38(6): Palmgren M, Cyhaniuk A, Yonan C, Potente E. Tracking healthcare utilization (cost) in pseudobulbar affect patients treated with Nuedexta. Value Heal. 2015;18(3):A284. doi: /j.jval Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6): doi: / Rudolph JL, Fonda JR, Hunt PR, et al. Association of pseudobulbar affect symptoms with quality of life and healthcare costs in veterans with traumatic brain injury. J Affect Disord. 2016;190: doi: /j.jad Demler T. The inpatient with dementia. US Pharm. 2014;39(11):HS18-HS Chan D-C, Kasper JD, Black BS, Rabins PV. Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis. J Gerontol A Biol Sci Med Sci. 2003;58(6): doi: /gerona/58.6.M548. S344 NOVEMBER

Sudden outbursts of crying or laughing can be a sign of fine acting. But for some, it could be PBA.

Sudden outbursts of crying or laughing can be a sign of fine acting. But for some, it could be PBA. Sudden outbursts of crying or laughing can be a sign of fine acting. But for some, it could be PBA. Danny Glover PseudoBulbar Affect (PBA) affects people with certain neurologic conditions or brain injuries.

More information

Pseudobulbar Affect: Burden of Illness in the USA

Pseudobulbar Affect: Burden of Illness in the USA Adv Ther (2012) 29(9):775 798. DOI 10.1007/s12325-012-0043-7 ORIGINAL RESEARCH Pseudobulbar Affect: Burden of Illness in the USA Jennifer Colamonico Andrea Formella Walter Bradley To view enhanced content

More information

Explaining Unpredictable Emotional Episodes

Explaining Unpredictable Emotional Episodes Explaining Unpredictable Emotional Episodes Pseudobulbar affect (PBA) after a stroke Stroke and Pseudobulbar Affect Pseudobulbar affect (PBA) is a medical condition that causes sudden and unpredictable

More information

3 How NUEDEXTA can help

3 How NUEDEXTA can help For people with certain neurologic conditions or brain injuries Uncontrollable crying and/or laughing may be a sign of PseudoBulbar Affect (PBA) PBA is treatable. Learn more with your PBA Kit. You re about

More information

Emerging Challenges in Primary Care: Pseudobulbar Affect: A Call to Action

Emerging Challenges in Primary Care: Pseudobulbar Affect: A Call to Action Emerging Challenges in Primary Care: 2017 Pseudobulbar Affect: A Call to Action 1 Faculty Gustavo Alva, MD, DFAPA Medical Director, ATP Clinical Research Volunteer Faculty (Assistant Clinical Professor)

More information

Pseudobulbar Affect: A Call to Action

Pseudobulbar Affect: A Call to Action Emerging Challenges in Primary Care: 2017 Pseudobulbar Affect: A Call to Action 1 Faculty Gustavo Alva, MD, DFAPA Medical Director, ATP Clinical Research Volunteer Faculty (Assistant Clinical Professor)

More information

PBA is treatable. Learn more inside.

PBA is treatable. Learn more inside. For people with certain neurologic conditions or brain injury Sudden, frequent, and uncontrollable crying and/or laughing that doesn t match how they feel may be a sign of PseudoBulbar Affect (PBA) PBA

More information

STROKE CLINICAL UPDATES. Approach to Patients with Pseudobulbar Affect in Stroke

STROKE CLINICAL UPDATES. Approach to Patients with Pseudobulbar Affect in Stroke STROKE CLINICAL UPDATES Approach to Patients with Pseudobulbar Affect in Stroke Introduction Pseudobulbar Affect (PBA) is a relatively common disorder of emotional expression that occurs in many neurological

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Nuedexta) Reference Number: CP.PMN.93 Effective Date: 12.05.17 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

Nuedexta (dextromethorphan hydrobromide/quinidine sulfate)

Nuedexta (dextromethorphan hydrobromide/quinidine sulfate) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.27 Subject: Nuedexta Page: 1 of 5 Last Review Date: March 16, 2018 Nuedexta Description Nuedexta (dextromethorphan

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates March 2017 By Darren Hein, PharmD Nuedexta is a fixed combination of dextromethorphan, an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist,

More information

Plan for Today. Brain Injury: 8/4/2017. Effective Services for People Living with Brain Injury. What is it & what causes it?

Plan for Today. Brain Injury: 8/4/2017. Effective Services for People Living with Brain Injury. What is it & what causes it? Effective Services for People Living with Brain Injury Jean Capler, MSW, LSW Local Support Network Leader The Rehabilitation Hospital of Indiana Department of Resource Facilitation Plan for Today Brain

More information

The Dangers of CTE. James Ryan Cox. Skylar Spriggs. Sawyer Solfest. Team THS131

The Dangers of CTE. James Ryan Cox. Skylar Spriggs. Sawyer Solfest. Team THS131 The Dangers of CTE James Ryan Cox Skylar Spriggs Sawyer Solfest Team THS131 Dec 10th, 2017 The human body works alike to a well-oiled machine, each vital organ working as a valuable gear or cog. Yet if

More information

Pseudobulbar affect (PBA) is a disorder of affective

Pseudobulbar affect (PBA) is a disorder of affective Pseudobulbar affect: When patients laugh or cry, but don t know why Disruption of neural circuitry undermines voluntary control of affect Benjamin Frock, MD PGY-1 Resident Vanderbilt University School

More information

Nuedexta (dextromethorphan hydrobromide/quinidine sulfate)

Nuedexta (dextromethorphan hydrobromide/quinidine sulfate) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.27 Subject: Nuedexta Page: 1 of 5 Last Review Date: September 15, 2016 Nuedexta Description Nuedexta

More information

Can Tango Help Improve Quality of Life for Patients with Parkinson s Disease?

Can Tango Help Improve Quality of Life for Patients with Parkinson s Disease? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Can Tango Help Improve Quality of Life

More information

Concussion Information

Concussion Information What is a Concussion? Concussion Information Information taken from the Sports Concussion Institute http://www.concussiontreatment.com A concussion is defined as a complex pathophysiological process that

More information

Lecture 13. The Nervous System. Lecture 13

Lecture 13. The Nervous System. Lecture 13 Lecture 13 The Nervous System Lecture 13 1. Introduction 2. Functions of the Nervous System 3. Neurons 4. CNS Brain and Spinal Cord 5. Peripheral Nervous System 6. Nervous System Health Concerns 1 The

More information

Nervous System Document Based Questions (DBQ)

Nervous System Document Based Questions (DBQ) Artifact A NFL Players Face Triple the Risk of Neurological Disease MIAMI (CBS Miami) A new report from the Centers for Disease Control and Prevention could break new ground on concussions suffered by

More information

PubMed via NLM Title: Nuedexta for the treatment of pseudobulbar affect (in ALS patients)

PubMed via NLM Title: Nuedexta for the treatment of pseudobulbar affect (in ALS patients) Litteratursökning PubMed via NLM 171006 Title: Nuedexta for the treatment of pseudobulbar affect (in ALS patients) Search terms Population: Population: ALS, MS, Demens, Stroke, TBI 1. "Amyotrophic Lateral

More information

Spectrum of Disinhibition Syndromes post-tbi.from PBA to Shopping

Spectrum of Disinhibition Syndromes post-tbi.from PBA to Shopping Spectrum of Disinhibition Syndromes post-tbi.from PBA to Shopping 2012 Annual Conference of the American Congress for Rehabilitation Medicine and the American Society for Neurorehabilitation, TBI Symposium

More information

What is Parkinson s disease?

What is Parkinson s disease? What is Parkinson s disease? 2 credit hour course Parkinson s disease (PD) is a disorder caused by a loss of nerve cells in a small part of the brain called the substantia nigra. This area of nerve cells

More information

ORIGINAL RESEARCH. Introduction

ORIGINAL RESEARCH. Introduction CNS Spectrums (2016), 21, 450 459. Cambridge University Press 2015. The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike

More information

Central nervous system

Central nervous system Central nervous system By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 7 th Lecture Lecture outline Review of structure & function. Symptoms, signs & tests. Specific diseases. Review of structure

More information

Movement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types

Movement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types Background Movement Disorders Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Early Studies Found some patients with progressive weakness

More information

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed. Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. Parkinson s Disease, Huntington s Disease and ALS: A brief overview of three diagnoses Leo G. Rafail,

More information

Supportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease

Supportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease Supportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease Ginger S. Johnson, PhD Vice President Defined Health Todd Sherer, PhD Chief Executive

More information

Concussion Update and Case Presentations

Concussion Update and Case Presentations Concussion Update and Case Presentations Cayce Onks, DO, MS, ATC Associate Professor Primary Care Sports Medicine Penn State Concussion Program Departments of Family Medicine and Orthopaedics I have no

More information

CHRONIC CONDITIONS FYI

CHRONIC CONDITIONS FYI CHRONIC CONDITIONS FYI AIDS More than 2,500 cases of HIV/AIDS have been identified in Nebraska. ALS (Amyotrophic Lateral Sclerosis) Approximately 95 people in Nebraska have ALS. As many as 800 Nebraskans

More information

MEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease

MEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease MEDIA BACKGROUNDER Multiple Sclerosis: A serious and unpredictable neurological disease Multiple sclerosis (MS) is a complex chronic inflammatory disease of the central nervous system (CNS) that still

More information

TBI as a Chronic Health Condition. John D. Corrigan, PhD

TBI as a Chronic Health Condition. John D. Corrigan, PhD TBI as a Chronic Health Condition John D. Corrigan, PhD Disclosures This research was supported by an interagency agreement between the US Department of Health and Human Services (HHS) Centers for Disease

More information

III./3.1. Movement disorders with akinetic rigid symptoms

III./3.1. Movement disorders with akinetic rigid symptoms III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.

More information

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) A Neurosurgical Treatment for Parkinson s Disease Parkinson s Disease Parkinson s disease is a common neurodegenerative disorder that affects about

More information

Concussion. Concussion is a disturbance of brain function caused by a direct or indirect force to the head.

Concussion. Concussion is a disturbance of brain function caused by a direct or indirect force to the head. Concussion Concussion is a disturbance of brain function caused by a direct or indirect force to the head. Disturbances of brain tissue is largely related to neurometabolic dysfunction rather then structural

More information

2011 Avanir Pharmaceuticals, Inc. April 2011

2011 Avanir Pharmaceuticals, Inc. April 2011 2011 Avanir Pharmaceuticals, Inc. April 2011 Forward-looking Statement Statements in this presentation that are not historical facts, including statements that are preceded by, followed by, or that include

More information

Concussion Management

Concussion Management Concussion Management Jennifer Gray, DO Medical Co-Director, ThinkSMART! Concussion Management Program Department of Physical Medicine and Rehabilitation St. Charles Hospital Residency Program Director,

More information

Chapter 8 & 9 DIABETES - HYPERTENSION - ELDERS

Chapter 8 & 9 DIABETES - HYPERTENSION - ELDERS Chapter 8 & 9 DIABETES - HYPERTENSION - ELDERS Lifestyle Choices The best single behavioral change Americans can make today to reduce morbidity and mortality is STOP SMOKING!!! Smoking is responsible for

More information

Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background

Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background Heather Benz, Ph.D. FDA Center for Devices and Radiological Health Neurological Degenerative Diseases Neurodegenerative

More information

POST STROKE LAUGHTER A CASE REPORT. Amarpreet Kaur*, Nor Zuraida Z*, Ng CG*, Aida SA*

POST STROKE LAUGHTER A CASE REPORT. Amarpreet Kaur*, Nor Zuraida Z*, Ng CG*, Aida SA* CASE REPORT POST STROKE LAUGHTER A CASE REPORT Amarpreet Kaur*, Nor Zuraida Z*, Ng CG*, Aida SA* *Department of Psychological Medicine, Faculty of Medicine,.. University of Malaya.. ABSTRACT Pathological

More information

MUSCULOSKELETAL AND NEUROLOGICAL DISORDERS

MUSCULOSKELETAL AND NEUROLOGICAL DISORDERS MUSCULOSKELETAL AND NEUROLOGICAL DISORDERS There are a wide variety of Neurologic and Musculoskeletal disorders which can impact driving safety. Impairment may be the result of altered muscular, skeletal,

More information

Biology 3201 Nervous System # 7: Nervous System Disorders

Biology 3201 Nervous System # 7: Nervous System Disorders Biology 3201 Nervous System # 7: Nervous System Disorders Alzheimer's Disease first identified by German physician, Alois Alzheimer, in 1906 most common neurodegenerative disease two thirds of cases of

More information

Dementia. Assessing Brain Damage. Mental Status Examination

Dementia. Assessing Brain Damage. Mental Status Examination Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological

More information

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral

More information

Dhiren J. Naidu MD FRCPC Dip. Sport Med.

Dhiren J. Naidu MD FRCPC Dip. Sport Med. Dhiren J. Naidu MD FRCPC Dip. Sport Med. Associate Professor, Division of Physical Medicine & Rehabilitation Faculty of Medicine & Dentistry Varsity Health, University of Alberta Team Physician - Oilers,

More information

Pseudobulbar Affect: an Under-recognized and Under-treated Neurological Disorder

Pseudobulbar Affect: an Under-recognized and Under-treated Neurological Disorder Adv Ther (2011) 28(7):586-601. DOI 10.1007/s12325-011-0031-3 ORIGINAL RESEARCH Pseudobulbar Affect: an Under-recognized and Under-treated Neurological Disorder Susan S. Work Jennifer A. Colamonico Walter

More information

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a

More information

The Person: Dementia Basics

The Person: Dementia Basics The Person: Dementia Basics Objectives 1. Discuss how expected age related changes in the brain might affect an individual's cognition and functioning 2. Discuss how changes in the brain due to Alzheimer

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

DVHIP. TBI: Clinical Issues, Controversies, and Learning from Patients. Defense and Veterans Head Injury Program. What is Neuropsychology?

DVHIP. TBI: Clinical Issues, Controversies, and Learning from Patients. Defense and Veterans Head Injury Program. What is Neuropsychology? TBI: Clinical Issues, Controversies, and Learning from Patients DVHIP Defense and Veterans Head Injury Program Richard A. Lanham, Jr., Ph.D. Assistant Professor Division of Medical Psychology Psychiatry

More information

International Brain Bee Syllabus 2012 Department of Neurosciences, Universiti Sains Malaysia

International Brain Bee Syllabus 2012 Department of Neurosciences, Universiti Sains Malaysia BRAIN DEVELOPMENT The cells of the nervous system connect with one another in trillions of remarkably specific patterns that form and change over the course of an organism s life. These connections develop

More information

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW WELCOME Parkinson s 101 for the Newly Diagnosed Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW Parkinson s Disease 101 Presenter for Today Cari Friedman, LCSW Patient and Family Service

More information

IT S ALL IN YOUR HEAD!

IT S ALL IN YOUR HEAD! IT S ALL IN YOUR HEAD! CARING FOR CONCUSSIONS IN YOUR COMMUNITY Stephen K Stacey, DO CPT, MC, USA OUTLINE Definition Epidemiology Diagnosis Evaluation Recovery Sequelae Prevention Resources for providers

More information

Common Causes of Brain Damage Cerebrovascular Disorders = Stroke Arteriosclerosis Ischemia and Excitotoxicity

Common Causes of Brain Damage Cerebrovascular Disorders = Stroke Arteriosclerosis Ischemia and Excitotoxicity 1 2 Common Causes of Brain Damage Cerebrovascular Disorders = Stroke Tumors Closed-head injuries Infections Neurotoxins Genetic Factors Cerebrovascular Disorders = Stroke May result from: Cerebral hemorrhage

More information

Multiple System Atrophy

Multiple System Atrophy Multiple System Atrophy This document has been prepared to help you become more informed about Multiple System Atrophy. It is designed to answer questions about the condition and includes suggestions on

More information

The Nervous System. We have covered many different body systems which automatically control and regulate our bodies.

The Nervous System. We have covered many different body systems which automatically control and regulate our bodies. The Nervous System The Nervous System We have covered many different body systems which automatically control and regulate our bodies. There is one master system which controls all of these other systems.

More information

Disclosures. Objectives 2/15/2014. Wright, Concussion Assessment, Management and Return to Sports

Disclosures. Objectives 2/15/2014. Wright, Concussion Assessment, Management and Return to Sports Concussion Assessment, Management and Return to Sports Wendy L. Wright, MS, APRN, FNP, FAANP Adult/Family Nurse Practitioner Owner Wright & Associates Family Healthcare Amherst Owner Wright & Associates

More information

Headway Victoria Epilepsy and Parkinson s Centre

Headway Victoria Epilepsy and Parkinson s Centre Headway Victoria Epilepsy and Parkinson s Centre Parkinson s Overview and Medication Shannon Oatway Community Education/ Awareness Coordinator What is Parkinson s Disease? The basics It is a chronic and

More information

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) A. The development of multiple cognitive deficits manifested by both 1 and 2 1 1. Memory impairment 2. One (or more) of the following

More information

CHRONIC CONDITIONS FYI

CHRONIC CONDITIONS FYI CHRONIC CONDITIONS FYI AIDS More than 2,500 cases of HIV/AIDS have been identified in Nebraska. Nationwide, this number is more than 1.2 million. ALS (Amyotrophic Lateral Sclerosis) There are 87 people

More information

THE NERVOUS SYSTEM FUNCTION

THE NERVOUS SYSTEM FUNCTION Nervous system THE NERVOUS SYSTEM The nervous system is comprised of the brain, the spinal cord and nerves. FUNCTION The nervous system has 3 general functions: a sensory function an interpretative function

More information

A Healthy Brain. An Injured Brain

A Healthy Brain. An Injured Brain A Healthy Brain Before we can understand what happens when a brain is injured, we must realize what a healthy brain is made of and what it does. The brain is enclosed inside the skull. The skull acts as

More information

THE POTENTIAL IMPACT OF VITALSTIM THERAPY ON HEALTHCARE COSTS: A White PaperVitalStim Therapy has significant

THE POTENTIAL IMPACT OF VITALSTIM THERAPY ON HEALTHCARE COSTS: A White PaperVitalStim Therapy has significant Dysphagia THE POTENTIAL IMPACT OF VITALSTIM THERAPY ON HEALTHCARE COSTS: A White PaperVitalStim Therapy has significant Contents potential to dramatically impact the health care costs arising from oropharyngeal

More information

Pathological laughing with syncope and occipital hypoperfusion as an unusual late effect of pontine infarct

Pathological laughing with syncope and occipital hypoperfusion as an unusual late effect of pontine infarct Neurology Asia 2010; 15(2) : 179 183 Pathological laughing with syncope and occipital hypoperfusion as an unusual late effect of pontine infarct Cheng-I Chu MD, Helen Po MD Department of Neurology, Mackay

More information

Evaluations. Dementia Update: A New National Plan for Alzheimer s Disease Research, Care and Services. Disclosure Statements.

Evaluations. Dementia Update: A New National Plan for Alzheimer s Disease Research, Care and Services. Disclosure Statements. Dementia Update: A New National Plan for Alzheimer s Disease Research, Care and Services June 21, 2012 Featured Speaker David Hoffman M.Ed. C.C.E, NYS DOH Office of Health Insurance Programs Clinical Associate

More information

COS SPORTS MEDICINE CONCUSSION ASSESSMENT FORM BASELINE TEST Adapted from SCAT3

COS SPORTS MEDICINE CONCUSSION ASSESSMENT FORM BASELINE TEST Adapted from SCAT3 COS SPORTS MEDICINE CONCUSSION ASSESSMENT FORM BASELINE TEST Adapted from SCAT3 Name Sport Examiner Name: Date of BASELINE TEST: Age Gender M / F COGNITIVE ASSESSMENT Orientation (1 pt each) What month

More information

Kristine Burkman, Ph.D. Staff Psychologist San Francisco VA Medical Center

Kristine Burkman, Ph.D. Staff Psychologist San Francisco VA Medical Center Kristine Burkman, Ph.D. Staff Psychologist San Francisco VA Medical Center ASAM Disclosure of Relevant Financial Relationships Content of Activity: ASAM Medical Scientific Conference 2013 Name Commercial

More information

I do not have any disclosures

I do not have any disclosures Alzheimer s Disease: Update on Research, Treatment & Care Clinicopathological Classifications of FTD and Related Disorders Keith A. Josephs, MST, MD, MS Associate Professor & Consultant of Neurology Mayo

More information

Evaluation of Parkinson s Patients and Primary Care Providers

Evaluation of Parkinson s Patients and Primary Care Providers Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,

More information

17 th WORKSHOP ON NEUROOTOLOGY. Dementia & Imbalance. DR. ATRI CHATTERJEE Assistant Professor. Neurology VMMC & SafdarJung Hospital New Delhi

17 th WORKSHOP ON NEUROOTOLOGY. Dementia & Imbalance. DR. ATRI CHATTERJEE Assistant Professor. Neurology VMMC & SafdarJung Hospital New Delhi 17 th WORKSHOP ON NEUROOTOLOGY Dementia & Imbalance DR. ATRI CHATTERJEE Assistant Professor. Neurology VMMC & SafdarJung Hospital New Delhi ?Association Dementia Imbalance?Causation balance: An even distribution

More information

Glutamate. By: Sascha Ridgewell, Hannah Straughan, Hunter Scripture, Caitlyn Wibbels, & Angelina Sutton

Glutamate. By: Sascha Ridgewell, Hannah Straughan, Hunter Scripture, Caitlyn Wibbels, & Angelina Sutton Glutamate By: Sascha Ridgewell, Hannah Straughan, Hunter Scripture, Caitlyn Wibbels, & Angelina Sutton Glutamate...What is it? The most important neurotransmitter for normal brain function. Nearly all

More information

7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery

7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery ABNORMAL PSYCHOLOGY SEVENTH EDITION Oltmanns and Emery PowerPoint Presentations Prepared by: Ashlea R. Smith, Ph.D. This multimedia and its contents are protected under copyright law. The following are

More information

A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH:

A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH: A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH: Amputee Coalition of America Mended Hearts National Federation of the Blind National Kidney Foundation

More information

Cheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy

Cheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:

More information

SUPPORT FEDERAL FUNDING FOR PARKINSON S DISEASE RESEARCH AND DRUG DEVELOPMENT

SUPPORT FEDERAL FUNDING FOR PARKINSON S DISEASE RESEARCH AND DRUG DEVELOPMENT SUPPORT FEDERAL FUNDING FOR PARKINSON S DISEASE RESEARCH AND DRUG DEVELOPMENT Parkinson s disease (PD) affects an estimated 750,000 to 1 million Americans. Currently, there is no treatment to slow, stop

More information

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials 1 Informative series of workshops featuring emerging trends in medical technology regulatory science, MDIC projects and subject matter experts sharing perspectives, progress and opportunities. Designing

More information

RAMBAM. Revolutionary New Treatment for Parkinson s Disease Tremors. Health Care Campus. Information Guide & Treatment Options

RAMBAM. Revolutionary New Treatment for Parkinson s Disease Tremors. Health Care Campus. Information Guide & Treatment Options RAMBAM Health Care Campus Revolutionary New Treatment for Parkinson s Disease Tremors Information Guide & Treatment Options Table of Contents Introduction 1 Parkinson s Disease Symptoms: Tremors 2 Current

More information

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Pathways bolt 16/6/06 20:38 Page 1 Pa t h w a y s A PARADIGM FOR DISEASE MANAGEMENT IN Pa r k i n s o n s Disease MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Clinical diagnosis Pa r k i n s o n s disease

More information

Index SLEEP MEDICINE CLINICS. Note: Page numbers of article titles are in boldface type.

Index SLEEP MEDICINE CLINICS. Note: Page numbers of article titles are in boldface type. 299 SLEEP MEDICINE CLINICS Sleep Med Clin 1 (2006) 299 303 Note: Page numbers of article titles are in boldface type. A Acid reflux, sleep disturbances in older adults related to, 238 Aging, alterations

More information

The PD You Don t See: Cognitive and Non-motor Symptoms

The PD You Don t See: Cognitive and Non-motor Symptoms The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals

More information

Vague Neurological Disorders

Vague Neurological Disorders Vague Neurological Disorders Dr. Philip Smalley MD FRCPC SVP & Global Chief Medical Officer RGA International Rose Conference, September 17, 2015 Agenda Vague neurological symptoms associated with: Alzheimer

More information

Decreasing the risk of falls by identifying and treating depression in the elderly. Oyinkan Akinmade, PT

Decreasing the risk of falls by identifying and treating depression in the elderly. Oyinkan Akinmade, PT Decreasing the risk of falls by identifying and treating depression in the elderly Oyinkan Akinmade, PT Role of Care Partners Pay attention to all aspects of your Seniors Allow seniors be as independent

More information

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:

More information

IMPAIRMENT OF THE NERVOUS SYSTEM

IMPAIRMENT OF THE NERVOUS SYSTEM IMPAIRMENT OF THE NERVOUS SYSTEM The following information provides criteria for the evaluation of permanent impairment resulting from dysfunction brain, spinal cord and cranial nerves and certain peripheral

More information

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY

More information

Brain Injury and Epilepsy

Brain Injury and Epilepsy Slide 1 Brain Injury and Epilepsy Presented by: Paula St. John, MA Education and Community Outreach Manager Minnesota Brain injury Alliance www.braininjurymn.org l 612-378-2742 800-669-6442 Slide 2 Objectives:

More information

MULTIPLE SCLEROSIS INTRODUCTION OBJECTIVES. When the student has finished this module, he/she will be able to:

MULTIPLE SCLEROSIS INTRODUCTION OBJECTIVES. When the student has finished this module, he/she will be able to: MULTIPLE SCLEROSIS INTRODUCTION Multiple sclerosis (MS) is a chronic disease of the nervous system. Multiple sclerosis causes inflammation and damage to the protective coatings in the brain and the nerves.

More information

Mary Fitzpatrick, ANP, MSCN Michelle Cameron, MD, PT

Mary Fitzpatrick, ANP, MSCN Michelle Cameron, MD, PT Mary Fitzpatrick, ANP, MSCN Michelle Cameron, MD, PT This continuing education activity is managed and accredited by Professional Education Service Group. The material presented in this activity represents

More information

Dementia is an overall term for a set of symptoms that is caused by disorders affecting the brain.

Dementia is an overall term for a set of symptoms that is caused by disorders affecting the brain. Vascular Dementia Vascular Dementia Other Dementias This information sheet provides an overview of a type of dementia known as vascular dementia. In this information sheet you will find: An overview of

More information

If you have dementia, you may have some or all of the following symptoms.

If you have dementia, you may have some or all of the following symptoms. About Dementia Dementia may be caused by a number of illnesses that affect the brain. Dementia typically leads to memory loss, inability to do everyday things, difficulty in communication, confusion, frustration,

More information

Identification number: TÁMOP /1/A

Identification number: TÁMOP /1/A Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master s Programmes at the University of Pécs and at the University of Debrecen Identification

More information

Mood Disorders-Major Depression

Mood Disorders-Major Depression Mood Disorders Paula Gibbs, MD Assistant Professor Department of Psychiatry Medical Director of 5West Med-Psych University of Utah Hospitals and Clinics Mood Disorders-Major Depression Key Points for Major

More information

Seth Smith MD, PharmD. Thank You!

Seth Smith MD, PharmD. Thank You! Seth Smith MD, PharmD Thank You! Concussion Headlines!!! Concussion Headlines!!! Concussion rules put kids health before winning games The Miami Herald 8/21/12 FHSAA's implementation of legislation goes

More information

Treatment of Parkinson s Disease: Present and Future

Treatment of Parkinson s Disease: Present and Future Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing

More information

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline REV 3/24/09 The UCNS Geriatric Neurology examination was established to determine the level of competence

More information

Neuropsychiatric Syndromes

Neuropsychiatric Syndromes Neuropsychiatric Syndromes Susan Czapiewski,MD VAHCS December 10, 2015 Dr. Czapiewski has indicated no potential conflict of interest to this presentation. She does intend to discuss the off-label use

More information

Brain Concussion: A Stealth Injury. Christine Schulman, RN, MS, CNS, CCRN Trauma & Critical Care CNS Legacy Health, Portland, Oregon Director, AACN

Brain Concussion: A Stealth Injury. Christine Schulman, RN, MS, CNS, CCRN Trauma & Critical Care CNS Legacy Health, Portland, Oregon Director, AACN Brain Concussion: A Stealth Injury Christine Schulman, RN, MS, CNS, CCRN Trauma & Critical Care CNS Legacy Health, Portland, Oregon Director, AACN Legacy Emanuel Medical Center Portland, Oregon Disclosures

More information

Concussion: Not Just For Athletes

Concussion: Not Just For Athletes Concussion: Not Just For Athletes M WASIF HUSSAIN, MBBS, FRCPC (NEUROLOGY) PRACTITIONER S DAY NOVEMBER 15, 2017 Overview Background Epidemiology Definitions Clinical Picture Concussion, PCS, CTE Concussion

More information

For carers and relatives of people with frontotemporal dementia and semantic dementia. Newsletter

For carers and relatives of people with frontotemporal dementia and semantic dementia. Newsletter For carers and relatives of people with frontotemporal dementia and semantic dementia Newsletter AUGUST 2008 1 Welcome Welcome to the August edition of our CFU Support Group Newsletter. Thanks to all of

More information

Decline in Mental Capacity

Decline in Mental Capacity Decline in Mental Capacity Elder Law: Issues, Answers and Opportunities ALI-ABA, February 23-24, 2006 Robert B. Fleming 1 FLEMING & CURTI, P.L.C. 330 N. Granada Ave. Tucson, Arizona 85701 www.elder-law.com

More information

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS

More information